{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-026712","form_type":"8-K","ticker":"TERN","cik":"0001831363","company_name":"Terns Pharmaceuticals, Inc.","filed_at":"2024-02-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.815989+00:00","generated_at":"2026-06-06T07:14:58.901028+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Terns Pharmaceuticals appoints Amy Burroughs as CEO and director effective Feb 7, 2024","bullets":["Amy Burroughs appointed CEO effective Feb 7, 2024; Jill Quigley becomes independent director after serving as Interim Senior Advisor.","Burroughs receives $625k salary, 50% target bonus, option to buy 1.25M shares, and 150k RSUs with price milestones at $15 and $20.","Burroughs previously CEO of Cleave Therapeutics, brings over 25 years experience in biotech and commercial roles.","Equity awards previously granted to Quigley will continue to vest based on her director service."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-026712","json":"https://secwatch.observer/filing/0001193125-24-026712.json","markdown":"https://secwatch.observer/filing/0001193125-24-026712.md","text":"https://secwatch.observer/filing/0001193125-24-026712.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1831363/000119312524026712/0001193125-24-026712-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1831363/000119312524026712/d718313d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T07:14:58.901028+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ac4dc2c1ba","claim":"Amy Burroughs was appointed as Chief Executive Officer and Director at Terns Pharmaceuticals, Inc..","evidence_excerpt":"pursuant to which Ms. Burroughs will serve as the Chief Executive Officer of Terns and has been appointed and elected as a member of the Board of Directors of Terns (the “Board”), effective as of February 7, 2024","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1831363/000119312524026712/0001193125-24-026712-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer and Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}